Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

159
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
159
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

177
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
177
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

177
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
177
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

364
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
364
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/ SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

Comparative Efficacy of Endovascular Revascularization Modalities for Symptomatic Infrapopliteal Peripheral Artery Disease: A Network Meta-Analysis.

JACC. Cardiovascular interventions·2026
Same author

Quality-of-Life Measurement in Migrants and Other Vulnerable Groups: Experience with Skindex-16 in Malta and Lebanon.

The British journal of dermatology·2026
Same author

Care-seeking among hepatocellular carcinoma patients in Uganda: health system navigation and its impact on diagnosis and survival in a prospective case-cohort study.

BMJ public health·2026
Same author

Calcium Channel Blockade Versus β-Blockade for Hypertension in Heart Failure With Preserved Ejection Fraction: A Randomized Crossover Trial.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Meningitis outbreak in Gaza: the role of malnutrition, displacement and attacks on healthcare.

BMJ global health·2026

Related Experiment Video

Updated: Dec 10, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K

Thrombosis in COVID-19.

Thomas C Hanff1,2, Amir M Mohareb3,4, Jay Giri1

  • 1Division of Cardiology, Department of Medicine, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

American Journal of Hematology
|August 29, 2020
PubMed
Summary

COVID-19 frequently causes thrombotic complications. This review explores hypercoagulability mechanisms, biomarkers, and therapeutic anticoagulation strategies for managing blood clots in COVID-19 patients.

More Related Videos

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
06:12

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Published on: July 21, 2023

886
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.3K

Related Experiment Videos

Last Updated: Dec 10, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K
Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots
06:12

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Published on: July 21, 2023

886
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.3K

Area of Science:

  • Infectious Diseases
  • Hematology
  • Critical Care Medicine

Background:

  • Thrombotic complications are a major cause of mortality and morbidity in COVID-19.
  • Hypercoagulability mechanisms, often seen in sepsis, may be amplified in COVID-19.

Purpose of the Study:

  • To review mechanisms of hypercoagulability in COVID-19.
  • To identify prognostic biomarkers for thrombotic events.
  • To evaluate therapeutic anticoagulation and fibrinolytic therapy in COVID-19.

Main Methods:

  • Literature review of mechanisms of hypercoagulability in sepsis and COVID-19.
  • Identification of potential prognostic biomarkers.
  • Analysis of observational studies on therapeutic anticoagulation.
  • Discussion of fibrinolytic therapy.

Main Results:

  • Several immune-mediated and systemic pathways contribute to hypercoagulability in COVID-19.
  • Biomarkers associated with these pathways may offer prognostic value.
  • Observational data suggests potential benefits of expanded therapeutic anticoagulation, though further research is needed.

Conclusions:

  • Understanding hypercoagulability mechanisms is crucial for managing COVID-19-associated thrombosis.
  • Targeted biomarker identification and therapeutic interventions, including anticoagulation and potentially fibrinolysis, warrant further investigation.